Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Dynamics of protein phosphorylation are regulated by the interplay of kinases and phosphatases. Current mass spectrometry-based phosphoproteomic approaches are extremely powerful in identifying and quantifying tens of thousands of phosphosites in single biological samples. However, whereas the mapping of phosphosites is successfully automated supporting high sample throughput, the characterization of responsible kinases and phosphatases still largely depends on laborious protein biochemical assays. To show direct (de)phosphorylation events, in vitro kinase or phosphatase assays using single substrates or peptide arrays are often used. Here, we describe the development of an in vitro phosphatase assay using whole proteome under native conditions as input. We employ this approach to study the PP1 and PP2A target repertoire, characterizing thousands of potential target sites. Focusing on PPP2R5E/B56ε-containing complexes, we combine in vitro with in vivo phosphoproteomics to characterize bona fide target sites, which highlight the role of PP2A in regulating stress granule assembly.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296510PMC
http://dx.doi.org/10.1016/j.crmeth.2025.101084DOI Listing

Publication Analysis

Top Keywords

pp2a target
8
target repertoire
8
kinases phosphatases
8
target sites
8
combination vivo
4
vitro
4
vivo vitro
4
vitro phosphoproteomics
4
phosphoproteomics determines
4
determines pp2a
4

Similar Publications

A prolyl oligopeptidase ligand blocks memory deficit in a repeated mild traumatic brain injury model.

Exp Neurol

September 2025

Division of Pharmacology and Pharmacotherapy, Drug Research Programme, Faculty of Pharmacy, University of Helsinki, Finland; Department of Pharmacology, Faculty of Medicine, University of Helsinki, Finland. Electronic address:

Traumatic brain injury (TBI) impacts up to 60 million people annually. Both severe TBIs and repeated mild TBIs (rmTBIs) can lead to persistent symptoms such as cognitive deficits, and even neurodegenerative diseases like chronic traumatic encephalopathy (CTE). To date, no therapies exist to mitigate the risk of CTE or other chronic symptoms post-TBI.

View Article and Find Full Text PDF

The mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, composed of amino acid (AA)-sensing (Ragulator/LAMTOR-Rag) and growth factor (GF)-sensing (AKT-TSC1/2-Rheb) axes, pivotally regulates intracellular anabolism and catabolism. mTORC1 deregulation is associated with various metabolic diseases, including cancer and diabetes. As a key regulator of nutrient signaling, mTORC1 integrates a variety of nutrient signals.

View Article and Find Full Text PDF

The identification of phosphatases that dephosphorylate specific sites in proteins remains a major challenge, particularly for the major class of serine/threonine-specific phosphatases, which function as holoenzymes. Here, we report the development of synthetic trap-peptides to identify phosphatases that bind to Tom6, a subunit of the mitochondrial translocase of the outer membrane (TOM) complex. The TOM complex is regulated by reversible phosphorylation, and although responsible kinases have been identified, the corresponding phosphatases so far remain unknown.

View Article and Find Full Text PDF

Aims: Antidiabetic drugs, sodium-glucose co-transporter-2 inhibitors (SGLT-2i), have demonstrated heart-saving properties independently of the diabetes status of a patient. We aimed to discover SGLT-2i-specific cardiac targets.

Materials And Methods: Two cardiac cell lines (AC16 and HCM) were treated with low-end therapeutic and 100- or 1000-fold dose of cana-, dapa and empagliflozin to investigate their influence on the (redox) proteome and thiol metabolome.

View Article and Find Full Text PDF

The Greatwall kinase inhibits PP2A-B55 phosphatase activity during mitosis to stabilise critical Cdk1-driven mitotic phosphorylation. Although Greatwall represents a potential oncogene and prospective therapeutic target, our understanding of the cellular and molecular consequences of chemical Greatwall inactivation remains limited. To address this, we introduce C-604, a highly selective Greatwall inhibitor, and characterise both immediate and long-term cellular responses to the chemical attenuation of Greatwall activity.

View Article and Find Full Text PDF